Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Jun 30, 2012
Filed with the SEC on Aug 8, 2012 and accepted by EDGAR at Aug 8, 2012, 20:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-04-01 to 2012-06-30 | $418.3m | us-gaap:Revenues |
| Revenue | 6 months2012-01-01 to 2012-06-30 | $857.0m | us-gaap:Revenues |
| Cost of revenue | 3 months2012-04-01 to 2012-06-30 | $104.5m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2012-01-01 to 2012-06-30 | $130.5m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2012-04-01 to 2012-06-30 | $196.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2012-01-01 to 2012-06-30 | $392.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2012-04-01 to 2012-06-30 | $117.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2012-01-01 to 2012-06-30 | $228.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2012-04-01 to 2012-06-30 | −$10.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2012-01-01 to 2012-06-30 | $80.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2012-04-01 to 2012-06-30 | $4.2m | us-gaap:InterestExpense |
| Interest expense | 6 months2012-01-01 to 2012-06-30 | $8.3m | us-gaap:InterestExpense |
| Income tax | 3 months2012-04-01 to 2012-06-30 | $20.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2012-01-01 to 2012-06-30 | $20.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-04-01 to 2012-06-30 | −$64.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2012-01-01 to 2012-06-30 | $26.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2012-04-01 to 2012-06-30 | −$0.31 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2012-01-01 to 2012-06-30 | $0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2012-04-01 to 2012-06-30 | −$0.31 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2012-01-01 to 2012-06-30 | $0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2012-04-01 to 2012-06-30 | 211,344,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2012-01-01 to 2012-06-30 | 212,957,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 6 months2012-01-01 to 2012-06-30 | $21.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2012-06-30 | $454.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-06-30 | $1.59bn | us-gaap:AssetsCurrent |
| Total assets | At period end2012-06-30 | $2.60bn | us-gaap:Assets |
| Current liabilities | At period end2012-06-30 | $379.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2012-06-30 | $1.36bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-06-30 | $1.04bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001047469-12-007979. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.